Flecainide Trial in ACM | SADS 2020 Virtual Conference
Flecainide Trial
Presented at the 2020 SADS International Virtual Conference
Join Crystal Tichnell, MGC, CGC from Johns Hopkins Hospital as she shares insights from the flecainide clinical trial in Arrhythmogenic Cardiomyopathy (ACM). Learn about the potential role of flecainide in reducing arrhythmia episodes, early trial findings, and what’s next for research in ACM treatments.
🔑 Key Takeaways:
Understanding flecainide’s potential role in ACM treatment
Preliminary trial results and safety profile
Implications for patient care and future studies
Featured Speaker: Crystal Tichnell, MGC, CGC – Genetic Counselor and Director of the ARVC Program at Johns Hopkins Hospital, specializing in ACM risk assessment, genetic testing, and research coordination.